New inhibitor quadrupole mutant PfDHFR as antimalaria candidate: Structure-based pharmacophore, molecular docking, ADMET, molecular dynamic, and chemical quantum study

Abstract

Genetic mutations in the dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) enzyme of the malaria parasite Plasmodium falciparum have been shown to reduce the effectiveness of several approved antimalarial drugs. This phenomenon has become a new challenge to the malaria control and treatment sector. As a result, the goal of this study is to identify the best compound with the potential to be an antimalarial agent by employing a good model pharmacophore generated by mutated PfDHFR as a receptor. Using a computational chemistry method, a structurebased pharmacophore was utilized to analyze 165,878 compounds from the zinc database. Subsequently, these compounds were further examined by molecular docking. Furthermore, the ADMET properties, including absorption, distribution, metabolism, excretion, and toxicity, of these drug-candidates have been assessed. Furthermore, molecular dynamic simulations were employed to investigate the stability of the compound-receptor complex, while DFT investigations were utilized to examine the electronic characteristics of these compounds. Overall findings indicated that the substance C431 (ZINC257280996) may be a potent PfDHFR-TS inhibitor due to its favorable binding energy of -42.26 kJ/mol, molecular dynamics simulations' indication of its stability, and its advantageous pharmacokinetic characteristics along with its non-toxic nature. The findings suggested that compound C431 could be a promising antimalarial candidate. Furthermore, this research provides guidance for improving the structure of compound C431 for future synthesis and verifies its antimalarial efficacy in vitro.

Keywords

• ADMET
• DFT Study
• Molecular Docking
• Molecular Dynamic
• Pharmacophore Modeling

References

1. [1] Rosenthal PJ. Malaria in 2022: Challenges and Progress. Am J Trop Med Hyg. 2022; 106(6): 1565–1567. https://doi.org/10.4269/AJTMH.22-0128
2. [2] World Health Organization. World Malaria Report 2022.
3. https://www.mmv.org/newsroom/news-resources-search/world-malaria-report-2022?gclid=CjwKCAiArfauBhApEiwAeoB7qA6Q9Va01OF0B6gGWENAb9rsmOPmSPlRmH6lzSGoDI6_aR_otcoEaxoC3G4QAvD_BwE (accessed November 15, 2023).
4. [3] Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020; 13: 4047–4060. https://doi.org/10.2147/IDR.S279433
5. [4] Sabe VT, Ntombela T, Jhamba LA, Maguire GEM, Govender T, Naicker T, Kruger HG. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur J Med Chem. 2021; 224: 113705. https://doi.org/10.1016/J.EJMECH.2021.113705
6. [5] Surabhi S, Singh B. Computer Aided Drug Design: An Overview. J Drug Deliv Ther. 2018; 8(5): 504–509. https://doi.org/10.22270/JDDT.V8I5.1894
7. [6] Muhammed MT, Aki-Yalcin E. Molecular docking: Principles, advances, and ıts applications in drug discovery. Lett Drug Des Discov. 2022; 21(3): 480–495. https://doi.org/10.2174/1570180819666220922103109
8. [7] Singh IV, Mishra S. Molecular docking analysis of pyrimethamine derivatives with Plasmodium falciparum dihydrofolate reductase. Bioinformation. 2018; 14(05): 232–235. https://doi.org/10.6026/97320630014232

9. [8] Hodoameda P. P. falciparum and ıts molecular markers of resistance to antimalarial drugs. In: Tyagi RK. (Eds). Plasmodium Species and Drug Resistance. IntechOpen, Inc., United Kingdonm, 2021, pp.1-21.
10. [9] Kreutzfeld O, Tumwebaze PK, Byaruhanga O, Katairo T, Okitwi M, Orena S, Rasmussen SA, Legac J, Conrad MD, Nsobya SL, Aydemir O, Bailey JA, Duffey M, Cooper RA, Rosenthal PJ. Decreased susceptibility to dihydrofolate reductase ınhibitors associated with genetic polymorphisms in Ugandan Plasmodium falciparum ısolates. J Infect Dis. 2022; 225(4): 696–704. https://doi.org/10.1093/INFDIS/JIAB435
11. [10] Posayapisit N, Pengon J, Prommana P, Shoram M, Yuthavong Y, Uthaipibull C, Kamchonwongpaisan S, Jupatanakul N. Transgenic pyrimethamine-resistant Plasmodium falciparum reveals transmission-blocking potency of P218, a novel antifolate candidate drug. Int J Parasitol. 2021; 51(8): 635–642. https://doi.org/10.1016/J.IJPARA.2020.12.002
12. [11] Rastelli G, Sirawaraporn W, Sompornpisut P, Vilaivan T, Kamchonwongpaisan S, Quarrell R, Lowe G, Thebtaranonth Y, Yuthavong Y. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: Structural basis of antifolate resistance. Bioorg Med Chem. 2000; 8(5): 1117–1128. https://doi.org/10.1016/S0968-0896(00)00022-5
13. [12] Tarnchompoo B, Chitnumsub P, Jaruwat A, Shaw PJ, Vanichtanankul J, Poen S, Rattanajak R, Wongsombat C, Tonsomboon A, Decharuangsilp S, Anukunwithaya T, Arwon U, Kamchonwongpaisan S, Yuthavong Y. Hybrid ınhibitors of malarial dihydrofolate reductase with dual binding modes that can forestall resistance. ACS Med Chem Lett. 2018; 9(12): 1235–1240. https://doi.org/10.1021/acsmedchemlett.8b00389
14. [13] Borkakoty B, Sarma K, Parida P, Prakash A, Mohapatra P, Mahanta J. In silico screening of antifolate based novel ınhibitors from Brucea mollis Wall. ex kurz against quadruple mutant drug resistant PfDHFR. Comb Chem High Throughput Screen. 2014; 17(8): 681–693. https://doi.org/10.2174/1386207317666140521153305
15. [14] Da Silva RSFL, Olanda CG, Fokoue HH, Sant’Anna CMR. Virtual screening techniques in drug discovery: Review and recent applications. Curr Top Med Chem. 2019; 19(19): 1751–1767. https://doi.org/10.2174/1568026619666190816101948
16. [15] Wang Z, Sun H, Shen C, Hu X, Gao J, Li D, Cao D, Hou T. Combined strategies in structure-based virtual screening. Phys Chem Chem Phys. 2020; 22(6): 3149–3159. https://doi.org/10.1039/C9CP06303J
17. [16] Kamchonwongpaisan S, Charoensetakul N, Srisuwannaket C, Taweechai S, Rattanajak R, Vanichtanankul J, Vitsupakorn D, Arwon U, Thongpanchang C, Tarnchompoo B, Vilaivan T, Yuthavong Y. Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities. Eur J Med Chem. 2020;195: 112263. https://doi.org/10.1016/J.EJMECH.2020.112263
18. [17] Somandi K, Seanego TD, Dlamini T, Maree M, de Koning CB, Vanichtanankul J, Rattanajak R, Saeyang T, Yuthavong Y, Kamchonwongpaisan S, Rousseau AL. Molecular docking studies, synthesis and biological evaluation of substituted pyrimidine-2,4-diamines as ınhibitors of Plasmodium falciparum dihydrofolate reductase. ChemMedChem. 2022; 17(22): e202200418. https://doi.org/10.1002/CMDC.202200418
19. [18] Opo FADM, Rahman MM, Ahammad F, Ahmed I, Bhuiyan MA, Asiri AM. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Sci Rep. 2021; 18(11): 4049. https://doi.org/10.1038/s41598-021-83626-x
20. [19] Kyei LK, Gasu EN, Ampomah GB, Mensah JO, Borquaye LS. An in silico study of the ınteractions of alkaloids from Cryptolepis sanguinolenta with Plasmodium falciparum dihydrofolate reductase and dihydroorotate dehydrogenase. J Chem. 2022; 2022: 1–26. https://doi.org/10.1155/2022/5314179
21. [20] Durán-Iturbide NA, Díaz-Eufracio BI, Medina-Franco JL. In silico ADME/Tox profiling of natural products: A focus on BIOFACQUIM. ACS Omega. 2020; 5(26): 16076–1684. https://doi.org/10.1021/acsomega.0c01581
22. [21] Azzam KM Al. SwissADME and pkCSM Webservers Predictors: an integrated online platform for accurate and comprehensive predictions for ın silico ADMET properties of artemisinin and its derivatives. Complex Use Miner Resour. 2023; 325(2): 14–21. https://doi.org/10.31643/2023/6445.13
23. [22] Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using Graph-Based Signatures. J Med Chem. 2015; 58(9): 4066–4072. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00104
24. [23] Purwanto BT, Hardjono S, Widiandani T, Nasyanka AL, Siswanto I. In silico study and ADMET prediction of N-(4-fluorophenylcarbamothioyl)benzamide derivatives as cytotoxic agents. J Hunan Univ Sci. 2021; 48(2): 78–85.
25. [24] Yeni Y, Rachmania RA. The prediction of pharmacokinetic properties of compounds in Hemigraphis alternata (Burm.F.) T. Ander leaves using pkCSM. Indones J Chem. 2022; (4): 1081–1089. https://doi.org/10.22146/ijc.73117
26. [25] Walters WP. Going further than Lipinski’s Rule in drug design. Expert Opin Drug Discov. 2012; 7(2): 99–107. https://doi.org/10.1517/17460441.2012.648612
27. [26] Jia CY, Li JY, Hao GF, Yang GF. A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discov Today. 2020; 25(1): 248–258. https://doi.org/10.1016/j.drudis.2019.10.014
28. [27] Taidi L, Maurady A, Britel MR. Molecular docking study and molecular dynamic simulation of human cyclooxygenase-2 (COX-2) with selected eutypoids. J Biomol Struct Dyn. 2022; 40(3): 1189–1204. https://doi.org/10.1080/07391102.2020.1823884
29. [28] Mosquera-Yuqui F, Lopez-Guerra N, Moncayo-Palacio EA. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of The Andean Region: Molecular docking and molecular dynamics simulations. J Biomol Struct Dyn. 2022; 40(5): 2010–2023. https://doi.org/10.1080/07391102.2020.1835716
30. [29] Menéndez CA, Accordino SR, Gerbino DC, Appignanesi GA. Hydrogen bond dynamic propensity studies for protein binding and drug design. PLoS One. 2016;11(10):e0165767. https://doi.org/10.1371/journal.pone.0165767
31. [30] El-Shamy NT, Alkoud AM, Hussein RK, Ibrahim MA, Alhamzani AG, Abou-Krisha MM. DFT, ADMET and molecular docking ınvestigations for the antimicrobial activity of 6,6’-Diamino-1,1’,3,3’-tetramethyl-5,5’-(4-chlorobenzylidene)bis[pyrimidine-2,4(1H,3H)-dione]. Molecules. 2022; 27(3): 620. https://doi.org/10.3390/molecules27030620
32. [31] Tsuneda T, Song JW, Suzuki S, Hirao K. On Koopmans’ Theorem in Density Functional Theory. J Chem Phys. 2010;133(17):174101. https://doi.org/10.1063/1.3491272
33. [32] Giordano D, Biancaniello C, Argenio MA, Facchiano A. Drug design by pharmacophore and virtual screening approach. Pharmaceuticals (Basel). 2022;15(5):646. https://doi.org/10.3390/ph15050646
34. [33] Imrie F, Bradley AR, Deane CM. Generating property-matched decoy molecules using deep learning. Bioinformatics. 2021; 37(15): 2134–2141. https://dx.doi.org/10.1093/bioinformatics/btab080
35. [34] Heinzke AL, Zdrazil B, Leeson PD, Young RJ, Pahl A, Waldmann H, Leach AR. A compound-target pairs dataset: differences between drugs, clinical candidates and other bioactive compounds. Sci Data. 2024;11(1):1160. https://doi.org/10.1038/s41597-024-03582-9.
36. [35] Naz S, Farooq U, Khan S, Sarwar R, Mabkhot YN, Saeed M, Alsayari A, Muhsinah AB, Ul-Haq Z. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against α-tryptophan synthase from Mycobacterium tuberculosis. J Biomol Struct Dyn. 2021;39(2):610-620. https://doi.org/10.1080/07391102.2020.1715259
37. [36] Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key topics in molecular docking for drug design. Int J Mol Sci. 2019;20(18):4574. https://doi.org/10.3390/IJMS20184574
38. [37] Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: Fast, Flexible, and free. J Comput Chem. 2005; 26(16): 1701–1718. https://doi.org/10.3390/IJMS20184574
39. [38] Zoete V, Cuendet MA, Grosdidier A, Michielin O. SwissParam: A Fast Force Field Generation Tool for Small Organic Molecules. J Comput Chem. 2011; 32(11): 2359–2368. https://doi.org/10.1002/JCC.21816
40. [39] Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I, Mackerell AD. CHARMM general force field: A Force field for drug-like molecules compatible with The CHARMM All-atom additive biological force fields. J Comput Chem. 2010; 31(4): 671–690. https://doi.org/10.1002/JCC.21367
41. [40] Boonstra S, Onck PR, Van Der Giessen E. CHARMM TIP3P Water model suppresses peptide folding by solvating the unfolded state. J Phys Chem B. 2016; 120(15): 3692–3698. https://doi.org/10.1021/acs.jpcb.6b01316
42. [41] Luo J, Xue ZQ, Liu WM, Wu JL, Yang ZQ. Koopmans’ Theorem for large molecular systems within density functional theory. J Phys Chem A. 2006; 110(43): 12005–12009. https://doi.org/10.1021/JP063669M